Medical Devices sales increased by 9.9% to $4.895 billion, driven by continued growth in Abbott's continuous glucose monitoring (CGM) systems and strength in Structural Heart products like Navitor and TriClip.

In March 2025, Abbott obtained CE Mark for its Volt™ Pulse Field Ablation (PFA) System to treat patients with atrial fibrillation. This approval allows Abbott to expand its offerings in the growing atrial fibrillation treatment market.

Established Pharmaceutical Products sales increased 2.7% to $1.260 billion, driven by a 9.3% increase in Key Emerging Markets, excluding the impact of foreign exchange. This indicates successful expansion in developing economies.

Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its diagnostic and medical devices businesses. In the three months ended March 31, 2025, Abbott recorded employee related severance and other charges of $34 million.

Research and development (R&D) expenses increased $32 million to $716 million, or 4.6 percent, in the first quarter of 2025. The increase in R&D expense was primarily driven by higher spending on various projects, indicating a focus on future product development.

Abbott expects to maintain an investment grade rating and declared a quarterly dividend of $0.59 per share, a 7.3% increase over the prior year. This demonstrates a commitment to financial stability and shareholder value.

Abbott faces lawsuits alleging that its preterm infant formula products cause necrotizing enterocolitis (NEC). A Missouri state court granted the plaintiff's motion for a new trial in March 2025, and Abbott appealed the ruling. Abbott is unable to reasonably estimate a range of possible loss related to these lawsuits.

Abbott is contesting Statutory Notices of Deficiency (SNODs) from the IRS for the 2017, 2018, 2019 and 2020 Federal tax years, totaling $1.052 billion. While Abbott intends to vigorously defend its filing positions, the outcome of these disputes could have a material impact on its financial position.

Abbott's net sales were unfavorably impacted by changes in foreign exchange rates in the first quarter, with the relatively stronger U.S. dollar decreasing total international sales by 4.5 percent and total sales by 2.8 percent.

Higher Diabetes Care sales were driven by continued growth in Abbott's continuous glucose monitoring (CGM) systems. CGM systems sales totaled $1.7 billion in the first three months of 2025, indicating a strong competitive position in this market.

In Structural Heart, the 14.7 percent increase in sales, excluding the effect of foreign exchange, primarily reflects growth in Navitor and TriClip products. These products are contributing to Abbott's competitive advantage in the structural heart market.

In Core Laboratory, sales increased 0.9 percent, excluding the effect of foreign exchange, due to continued deployment of Abbott's Alinity® testing platform, mostly offset by the impact of volume-based procurement programs in China. Alinity deployment helps maintain competitiveness despite pricing pressures.

Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its diagnostic and medical devices businesses. This indicates a focus on improving operational efficiency.

The gross profit margin percentage was 52.8 percent for the first quarter of 2025 compared to 50.5 percent for the first quarter of 2024. The increase reflects the favorable impacts of gross margin improvement initiatives and foreign exchange.

Selling, general and administrative expenses increased $102 million, or 3.5 percent, in the first quarter of 2025 as higher selling and marketing spending to drive growth across various businesses was partially offset by the favorable impact of foreign exchange.

Abbott obtained CE Mark for its Volt™ Pulse Field Ablation (PFA) System to treat patients with atrial fibrillation, demonstrating innovation in cardiac rhythm management.

Sales increased due to continued deployment of Abbott's Alinity® testing platform, indicating a focus on technological upgrades in diagnostic systems.

Higher Diabetes Care sales were driven by continued growth in Abbott's continuous glucose monitoring (CGM) systems, indicating technological leadership in this market.

Abbott repaid the $1.0 billion outstanding principal amount of its 2.95% Notes upon maturity in March 2025. This action strengthens the balance sheet and reduces future interest expense.

Abbott declared a quarterly dividend of $0.59 per share, which represents an increase of 7.3 percent over the prior year. This indicates a commitment to returning capital to shareholders.

The board of directors authorized the repurchase of up to $7 billion of Abbott common shares, from time to time. This authorization provides flexibility for capital deployment and may support share price.

The provided 10-Q filing does not contain any specific information regarding Environmental, Social, and Governance (ESG) initiatives undertaken by Abbott Laboratories during the reported period. Therefore, it is not possible to assess the company's performance in this area based on the available information.

Abbott's primary markets are highly competitive and subject to substantial government regulations throughout the world. This highlights the challenging market environment in which Abbott operates.

Diagnostic Products sales growth continued to be impacted by the decline in COVID-19 testing-related sales. This reflects the changing market dynamics as the pandemic subsides.

Diagnostic Products sales growth continued to be impacted by the impact of volume-based procurement programs in China. This highlights the influence of regulatory and purchasing policies on Abbott's performance in key markets.